Pharmaceuticals, Biotechnology and Life Sciences
-FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020- -Application supported…
ZELNORM approved by FDA in March 2019 after thorough safety review Alfasigma USA has begun national reintroduction of ZELNORM to…
– First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread…
SEATTLE–(BUSINESS WIRE)–#biologics–Cyrus Biotechnology, Inc., a Seattle-based biotech software company specializing in the use and commercialization of Rosetta, the world’s leading…
DUBLIN–(BUSINESS WIRE)–The “Global Stem Cell and Regenerative Therapy Market: A Research Outlook” report has been added to ResearchAndMarkets.com’s offering. Growth…
Medical Marijuana, the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, record revenue of $20.7 million in the second quarter of 2019, a 30.8% increase over the same quarter in 2018.
WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today…
Moves into new San Francisco Bay Area R&D facility, comprising approximately 15,700-square-feet of office and lab space, including cGMP-capable manufacturing…
SAN FRANCISCO–(BUSINESS WIRE)–#ai–First paragraph, second sentence of release should read: Recently raising a $5.2M USD series seed co-led by OCA…
ESSA posted a net loss of $3.3 million for the second quarter, 2019, compared to a net loss of $2.9 million for the same period last year, pointing out R&D expenses to be $1.95 million, compared to $0.99 million last year the same period.